Molecular Cancer Therapeutics · 2013 · 56 citations · 27 references
MedicineOncologyPharmacologyCancer PharmacologyMetastasisMolecular OncologyApoptosis ResistanceBreast Cancer PharmacotherapyMetastatic Breast CancerMicrotubule-targeting AgentsMitotic InhibitorsTargeted Cancer TherapyAntiproliferative AgentsAntiproliferative Drug ActionAurora Kinase InhibitionMetastatic Breast Cancer TreatmentMicrotubule-targeting Combination TherapyTaxane ChemotherapyTaxane TherapyTriple-negative Breast Cancer Therapy
Breast cancer is the most prevalent malignancy affecting women and ranks second in cancer-related deaths, in which death occurs primarily from metastatic disease. Triple-negative breast cancer (TNBC) is a more aggressive and metastatic subtype of breast cancer that is initially responsive to treatment of microtubule-targeting agents (MTA) such as taxanes. Recently, we reported the characterization of AMG 900, an orally bioavailable, potent, and highly selective pan-Aurora kinase inhibitor that is active in multidrug-resistant cell lines. In this report, we investigate the activity of AMG 900 alone and in combination with two distinct classes of MTAs (taxanes and epothilones) in multidrug-resistant TNBC cell lines and xenografts. In TNBC cells, AMG 900 inhibited phosphorylation of histone H3 on Ser(10), a proximal substrate of Aurora-B, and induced polyploidy and apoptosis. Furthermore, AMG 900 potentiated the antiproliferative effects of paclitaxel and ixabepilone at low nanomolar concentrations. In mice, AMG 900 significantly inhibited the growth of MDA-MB-231 (F(11); parental), MDA-MB-231 (F(11)) PTX-r (paclitaxel-resistant variant), and DU4475 xenografts. The combination of AMG 900 with docetaxel enhanced tumor inhibition in MDA-MB-231 (F(11)) xenografts compared with either monotherapy. Notably, combining AMG 900 with ixabepilone resulted in regressions of MDA-MB-231 (F(11)) PTX-r xenografts, in which more than 50% of the tumors failed to regrow 75 days after the cessation of drug treatment. These findings suggest that AMG 900, alone and in combination with MTAs, may be an effective intervention strategy for the treatment of metastatic breast cancer and provide potential therapeutic options for patients with multidrug-resistant tumors.
27
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis, Sohrab P. Shah, Suet‐Feung Chin et al. · Nature · 2012 · 6.4K citations · Full text
Life Sciences, Genetics, Oncology +14
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat, Joel S. Parker, Olga Karginova et al. · Breast Cancer Research · 2010 · 2.1K citations · Full text
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo, Nicole L. Solimini, Stephen J. Elledge · Cell · 2009 · 1.8K citations · Full text
Medicine, Cancer Biology, Oncology +14
A mechanism linking extra centrosomes to chromosomal instability
Neil J. Ganem, Susana A. Godinho, David Pellman · Nature · 2009 · 1.4K citations · Full text